New strategies to develop new medications for lung cancer and metastasis
作者： Yujie Zhao , Alex A. Adjei
DOI: 10.1007/S10555-015-9553-5
关键词:
摘要: With the advances in cancer and molecular biology rapid progress genomics, significant has been made treatment of lung past decade. Targeted therapies have developed for nonsmall cell (NSCLC), improvement survival achieved. There is still, however, no cure advanced NSCLC. Resistance to initial therapy universal, lethal outcome metastatic disease still remains. Approaches preventing metastases overcoming resistance are necessary ensure long-term patients with cancer.
springer.com
elsevier.com
sci-hub.se 参考文章(73)
Julie R Brahmer, Leora Horn, Leena Gandhi, David R Spigel, Scott Joseph Antonia, Naiyer A Rizvi, John D Powderly, Rebecca Suk Heist, Richard D Carvajal, David Michael Jackman, Lecia V Sequist, David C Smith, Philip D Leming, Suzanne Louise Topalian, F Stephen Hodi, Mario Sznol, Christopher Harbison, Georgia Kollia, Ashok Kumar Gupta, Scott N Gettinger, None, Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. Journal of Clinical Oncology. ,vol. 32, pp. 8112- 8112 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.8112
Mark M Awad, Alice T Shaw, ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond Clinical advances in hematology & oncology. ,vol. 12, pp. 429- 439 ,(2014)
Haidong Dong, Gefeng Zhu, Koji Tamada, Lieping Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nature Medicine. ,vol. 5, pp. 1365- 1369 ,(1999) , 10.1038/70932
Alice Tsang Shaw, D Ross Camidge, Jeffrey A. Engelman, Benjamin J. Solomon, Eunice Lee Kwak, Jeffrey W. Clark, Ravi Salgia, Geoffrey Shapiro, Yung-Jue Bang, Weiwei Tan, Lesley Tye, Keith D. Wilner, Patricia Stephenson, Marileila Varella-Garcia, Kristin Bergethon, A. John Iafrate, Sai-Hong Ignatius Ou, Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Journal of Clinical Oncology. ,vol. 30, pp. 7508- 7508 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.7508
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Sen Zhang, Frank Wang, Jeffrey Keats, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Xiaotian Zhu, Juan J. Miret, David Dalgarno, Narayana I. Narasimhan, Tim Clackson, William C. Shakespeare, Victor M. Rivera, Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) Cancer Research. ,vol. 70, ,(2010) , 10.1158/1538-7445.AM10-LB-298
Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi, Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Clinical Cancer Research. ,vol. 12, pp. 5764- 5769 ,(2006) , 10.1158/1078-0432.CCR-06-0714
Denis Maillet, Isabelle Martel-Lafay, Dominique Arpin, Maurice Pérol, Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. Journal of Thoracic Oncology. ,vol. 8, ,(2013) , 10.1097/JTO.0B013E318288DC2D
Justin F. Gainor, Sai-Hong Ignatius Ou, Jennifer Logan, Lawrence F. Borges, Alice T. Shaw, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology. ,vol. 8, pp. 1570- 1573 ,(2013) , 10.1097/JTO.0000000000000029
Padmanee Sharma, Klaus Wagner, Jedd D. Wolchok, James P. Allison, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps Nature Reviews Cancer. ,vol. 11, pp. 805- 812 ,(2011) , 10.1038/NRC3153